Development of a novel nano-sized anti-VEGFA nanobody with enhanced physicochemical and pharmacokinetic properties

References

• El‐Kenawi AE, El-Remessy AB. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol. 2013;170:712–729.
   PubMed Web of Science ®Google Scholar
• Mendler CT, Friedrich L, Laitinen I, et al. High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation. MAbs. 2015;7:96–109.
   PubMed Web of Science ®Google Scholar
• Herrington-Symes AP, Farys M, Khalili H, et al. Antibody fragments: prolonging circulation half-life special issue-antibody research. Adv Biosci Biotechnol. 2013;4:689–698.
   Google Scholar
• Wu D, Gao Y, Qi Y, et al. Peptide-based cancer therapy: opportunity and challenge. Cancer Lett. 2014;351:13–22.
   PubMed Web of Science ®Google Scholar
• Kong Q, Yao Y, Chen R, et al. [Progress in nanobody and its application in diagnosis]. Sheng Wu Gong Cheng Xue Bao. 2014;30:1351–1361.
   PubMedGoogle Scholar
• Nelson AL. Antibody fragments: hope and hype. MAbs. 2010;2:77–83.
   PubMed Web of Science ®Google Scholar
• Harmsen M, De Haard H. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol. 2007;77:13–22.
   PubMed Web of Science ®Google Scholar
• Kijanka M, Dorresteijn B, Oliveira S, et al. Nanobody-based cancer therapy of solid tumors. Nanomedicine (Lond). 2015;10:161–174.
   PubMed Web of Science ®Google Scholar
• Dingermann T. Book review: therapeutic proteins: strategies to modulate their plasma half‐lives. Biotechnology J. 2013;8:163–164.
   Google Scholar
• Kontermann RE. Half?life modulating strategies?an introduction. Therapeutic proteins: strategies to modulate their plasma half-lives. 2012.
   Google Scholar
• Samoudi M, Tabandeh F, Minuchehr Z, et al. Rational design of hyper-glycosylated interferon beta analogs: a computational strategy for glycoengineering. J Mol Graph Model. 2015;56:31–42.
   PubMed Web of Science ®Google Scholar
• Maleki A, Madadkar-Sobhani A, Roohvand F, et al. Design, modeling, and expression of erythropoietin cysteine analogs in Pichia pastoris: improvement of mean residence times and in vivo activities through cysteine-specific PEGylation. Eur J Pharm Biopharm. 2012;80:499–507.
   PubMed Web of Science ®Google Scholar
• Ahangari Cohan R, Madadkar-Sobhani A, Khanahmad H, et al. Design, modeling, expression, and chemoselective PEGylation of a new nanosize cysteine analog of erythropoietin. Int J Nanomedicine. 2011;6:1217–1227.
   PubMed Web of Science ®Google Scholar
• Hamidi M, Rafiei P, Azadi A. Designing PEGylated therapeutic molecules: advantages in ADMET properties. Expert Opin Drug Discov. 2008;3:1293–1307.
   PubMed Web of Science ®Google Scholar
• Sleep D. Albumin and its application in drug delivery. Expert Opin Drug Deliv. 2015;12:793–812.
   PubMed Web of Science ®Google Scholar
• Schmidt SR. Fusion proteins: applications and challenges. Fusion protein technologies for biopharmaceuticals. John Wiley & Sons, Inc.; 2013.
   Google Scholar
• Turecek PL, Bossard MJ, Schoetens F, et al. PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J Pharm Sci. 2016;105:460–475.
   PubMed Web of Science ®Google Scholar
• Garay RP, El-Gewely R, Armstrong JK, et al. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv. 2012;9:1319–1323.
   PubMed Web of Science ®Google Scholar
• Harari D, Kuhn N, Abramovich R, et al. Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis. J Biol Chem. 2014;289:29014–29029.
   PubMed Web of Science ®Google Scholar
• Schlapschy M, Binder U, Börger C, et al. PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins. Protein Eng Des Sel. 2013;26:489–501.
   PubMed Web of Science ®Google Scholar
• Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc. 2010;5:725–738.
   PubMed Web of Science ®Google Scholar
• Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera – a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605–1612.
   PubMed Web of Science ®Google Scholar
• Phillips JC, Braun R, Wang W, et al. Scalable molecular dynamics with NAMD. J Comput Chem. 2005;26:1781–1802.
   PubMed Web of Science ®Google Scholar
• Mackerell AD Jr, Feig M, Brooks CL III. Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J Comput Chem. 2004;25:1400–1415.
   PubMed Web of Science ®Google Scholar
• Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996;14:33–38. 27–28.
   PubMed Web of Science ®Google Scholar
• Kazemi-Lomedasht F, Behdani M, Bagheri KP, et al. Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody. Mol Immunol. 2015;65:58–67.
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254.
   PubMed Web of Science ®Google Scholar
• Zvonova EA, Ershov AV, Ershova OA, et al. PASylation technology improves recombinant interferon-β1b solubility, stability, and biological activity. Appl Microbiol Biotechnol. 2017;101:1975–1987.
   PubMed Web of Science ®Google Scholar
• Ghavamipour F, Shahangian SS, Sajedi RH, et al. Development of a highly-potent anti-angiogenic VEGF8-109 heterodimer by directed blocking of its VEGFR-2 binding site. FEBS J. 2014;281:4479–4494.
   PubMed Web of Science ®Google Scholar
• Xu J, Zhang Y. How significant is a protein structure similarity with TM-score =0.5? Bioinformatics. 2010;26:889–895.
   PubMed Web of Science ®Google Scholar
• Skerra A, Theobald I, Schlapschy M, inventors; Technische Universitat Munchen, Munich (DE), assignee. Biological active proteins having increased in vivo and/or in vitro stability. US Patent 9260494 B2. 2013.
   Google Scholar
• Morath V, Bolze F, Schlapschy M, et al. PASylation of murine leptin leads to extended plasma half-life and enhanced in vivo efficacy. Mol Pharm. 2015;12:1431–1442.
   PubMed Web of Science ®Google Scholar
• Schlapschy M, Theobald I, Mack H, et al. Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. Protein Eng Des Sel. 2007;20:273–284.
   PubMed Web of Science ®Google Scholar
• Oldham RK, Dillman RO. Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol. 2008;26:1774–1777.
   PubMed Web of Science ®Google Scholar
• Kromann-Hansen T, Oldenburg E, Yung KW, et al. A Camelid-derived antibody fragment targeting the active site of a serine protease balances between inhibitor and substrate behavior. J Biol Chem. 2016;291:15156–15168.
   Web of Science ®Google Scholar
• Harari D, Kallweit N, Abramovich R, et al. 73: Enhanced in vivo efficacy using a novel long-life type I interferon variant in a mouse model of multiple sclerosis. Cytokine. 2014;70:45.
   Web of Science ®Google Scholar
• Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–185.
   PubMed Web of Science ®Google Scholar
• Liang C-C, Park AY, Guan J-L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2:329–333.
   PubMed Web of Science ®Google Scholar
• Hoefman S, Ottevaere I, Baumeister J, et al. Pre-clinical intravenous serum pharmacokinetics of albumin binding and non-half-life extended Nanobodies®. Antibodies. 2015;4:141–156.
   Web of Science ®Google Scholar
• Van Roy M, Ververken C, Beirnaert E, et al. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015;17:135.
   PubMed Web of Science ®Google Scholar
• Vugmeyster Y, Entrican CA, Joyce AP, et al. Pharmacokinetic, biodistribution, and biophysical profiles of TNF nanobodies conjugated to linear or branched poly (ethylene glycol). Bioconjug Chem. 2012;23:1452–1462.
   PubMed Web of Science ®Google Scholar
• Hedayati MH, Norouzian D, Aminian M, et al. Molecular design, expression and evaluation of PASylated human recombinant erythropoietin with enhanced functional properties. Protein J. 2017;36:36–48.
   PubMed Web of Science ®Google Scholar